Company Overview
About Nabla Bio
Nabla Bio is a Harvard spinout biotech company using AI-driven generative protein design to develop antibodies against multipass membrane proteins — a class of drug targets including GPCRs (G protein-coupled receptors), ion channels, and transporters that are implicated in numerous diseases but have been historically undruggable with antibody therapies due to their complex 3D structure embedded in the cell membrane. A Y Combinator graduate, Nabla Bio raised $37 million total including a $26 million Series A led by Radical Ventures, and secured strategic collaborations with AstraZeneca, Bristol Myers Squibb, and Takeda worth $550 million+ in upfront and milestone payments plus royalties.
Business Model & Competitive Advantage
Nabla Bio's generative protein design platform creates novel antibody architectures specifically optimized for binding to multipass membrane proteins — using deep learning to design proteins that can access and bind the exposed loops and domains of these structurally complex targets that conventional antibody discovery methods fail to address reliably. GPCRs alone are targets of approximately 34% of all FDA-approved drugs, but mainly through small molecules; antibodies offer advantages including higher specificity and longer half-life that small molecules can't achieve.
Competitive Landscape 2025–2026
In 2025, Nabla Bio competes in the AI drug discovery and protein design market with Recursion Pharmaceuticals (RXRX), AbSci (AI antibody design), and Insilico Medicine for AI-powered drug target and antibody discovery, and with traditional antibody discovery companies (AbCellera, Sorrento, Regeneron's VelociSuite) for GPCRs and ion channel antibody programs. The $550M+ partnership revenue from AstraZeneca, BMS, and Takeda validates the platform's commercial appeal to major pharmaceutical companies that need access to the multipass membrane protein antibody capabilities Nabla Bio has built. Radical Ventures' Series A lead reflects deep AI research investment thesis. The 2025 strategy focuses on advancing partnership programs toward the clinic, identifying and developing proprietary pipeline programs in GPCR oncology and neurological disease indications, and expanding the computational protein design platform to additional target classes.
Recent Activity
View all →Key Differentiators
Emerging Innovator
Nabla Bio is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Browser Use
Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Nabla Bio with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Nabla Bio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Nabla Bio Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Nabla Bio vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →